NAD+ Therapy: Cellular Metabolism, Precursor Pathways, and Longevity Research

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It is not a peptide, and it is worth stating that plainly at the outset, because NAD+ is frequently discussed alongside peptide therapies and the biochemistry is entirely different. NAD+ is a redox cofactor and an enzymatic substrate — and the fact that it is consumed as a substrate, not merely recycled, is the central premise behind supplementing it.

What NAD+ Does in the Cell

Redox Cofactor Function

In its oxidized form, NAD+ accepts electrons to become NADH; NADH donates them back. This cycling is the electron-carrying backbone of glycolysis, the citric acid cycle, fatty acid oxidation, and oxidative phosphorylation. Without adequate NAD+, mitochondrial ATP production is constrained regardless of substrate availability.

Substrate for NAD+-Consuming Enzymes

The second role is the one that drives the aging literature. Three enzyme families cleave NAD+ and consume it in the process:

• Sirtuins (SIRT1–SIRT7) — NAD+-dependent deacetylases governing mitochondrial biogenesis, DNA repair, inflammatory signaling, and circadian gene expression. Sirtuin activity is directly limited by NAD+ availability.
• PARPs (poly-ADP-ribose polymerases) — activated by DNA strand breaks. PARP1 is a substantial NAD+ consumer, and sustained genotoxic stress can materially deplete cellular pools.
• CD38 — an NAD+ glycohydrolase whose expression increases with age and with inflammatory signaling, and which is now regarded as a principal driver of age-related NAD+ decline.

Why Levels Decline With Age

Tissue NAD+ concentrations fall with age across multiple species. The decline appears to be driven from both directions: reduced salvage-pathway throughput on the supply side, and increased CD38 and PARP consumption on the demand side. The consequence — reduced sirtuin activity and impaired mitochondrial function — is what positions NAD+ restoration as a target rather than merely a marker.

Biosynthesis: Why the Precursor Question Matters

The Salvage Pathway

Most cellular NAD+ is regenerated rather than synthesized de novo. Nicotinamide is recycled by nicotinamide phosphoribosyltransferase (NAMPT) to nicotinamide mononucleotide (NMN), which NMN adenylyltransferases convert to NAD+. NAMPT is the rate-limiting step, which makes it the pathway's principal bottleneck.

Precursor Entry Points

The Bioavailability Problem With Oral NAD+

Intact NAD+ is a large, charged dinucleotide. It is poorly absorbed orally and is substantially degraded to nicotinamide in the gut before reaching circulation. This is the specific reason parenteral routes are used: not because injection is inherently superior, but because oral NAD+ largely does not arrive as NAD+.

Administration Routes in Clinical Practice

The following is educational context on how NAD+ is administered in practice. It is not a dosing recommendation, and NAD+ administration should be directed by a licensed provider.

Intravenous Infusion

IV NAD+ is the most established parenteral route. Infusions are characteristically slow — commonly several hours — because rapid administration reliably produces chest tightness, abdominal cramping, nausea, and flushing. These effects are infusion-rate dependent and resolve when the rate is reduced, which is why unsupervised rapid administration is inappropriate.

Subcutaneous and Intramuscular

Subcutaneous NAD+ is used for maintenance between infusions, typically at considerably smaller per-dose amounts and with correspondingly milder acute effects. Injection-site discomfort is common.

Intranasal and Sublingual

These routes are used in practice for convenience. Absorption characteristics for intact NAD+ by these routes are not well characterized.

Oral Precursors

For most patients pursuing long-term NAD+ support rather than an acute protocol, oral precursors — NR or NMN — are the practical approach, since they are absorbed and enter the salvage pathway normally. The trade-off is between the larger, faster increase a parenteral route produces and the sustainability of daily oral dosing.

What the Human Evidence Supports

Precursor Trials

Human trials of NR and NMN have consistently demonstrated that oral precursor supplementation raises blood NAD+ metabolite concentrations. That much is well established. Downstream clinical endpoints are far less settled: trials have reported variable and often modest effects on insulin sensitivity, muscle function, aerobic capacity, and inflammatory markers, with results differing by population, dose, and duration.

The Gap Between Biomarker and Outcome

The honest summary is that raising NAD+ is demonstrated, while translating that increase into measurable clinical benefit in generally healthy adults is not. Patients encountering enthusiastic claims about NAD+ should understand where the evidence is solid and where it is extrapolated.

Areas of Active Investigation

Ongoing research directions include neurodegenerative disease, cardiometabolic function, chemotherapy-induced peripheral neuropathy, and heart failure. None has produced a definitive result.

Combination and Adjacent Approaches

NAD+ is frequently discussed alongside other mitochondrial-support compounds. Methylene blue, for instance, acts as an alternative electron carrier in the mitochondrial electron transport chain — a mechanistically different intervention aimed at overlapping physiology; the rationale for combining them is discussed in our review of methylene blue and NMN stacking. NAD+ protocols delivered by infusion also commonly incorporate B-vitamin cofactors, since nicotinamide metabolism intersects with methylation pathways that depend on B12 and folate.

Safety and Monitoring

Infusion-Related Effects

The dominant safety consideration for IV NAD+ is rate-dependent: chest pressure, abdominal cramping, nausea, flushing, and headache. These are uncomfortable rather than dangerous when managed by slowing the infusion, but they require the infusion be supervised.

Methylation Consideration

Nicotinamide clearance proceeds through methylation, consuming S-adenosylmethionine. Whether sustained high-dose precursor supplementation meaningfully depletes methyl donors is debated; some clinicians monitor or co-supplement accordingly.

Populations Requiring Caution

Patients with active malignancy warrant particular discussion: NAD+ supports DNA repair and cellular energetics in all cells, and the theoretical implications for tumor biology are unresolved. Pregnancy and lactation lack data. Patients on chemotherapy should not add NAD+ protocols without oncology input.

Frequently Asked Questions About NAD+

What is NAD+ therapy?

NAD+ therapy refers to administering nicotinamide adenine dinucleotide — or a precursor such as NMN or NR — to counter the age-related decline in cellular NAD+. It is delivered by IV infusion, subcutaneous injection, or oral precursor supplementation, depending on the goal.

NAD+ vs NMN — which is better?

They address the same pathway from different points. NMN is an oral precursor one enzymatic step from NAD+, absorbed and converted normally, suited to sustained daily use. Direct NAD+ is given parenterally because it is poorly absorbed orally, and is used where a rapid, larger increase is the objective. Neither is universally superior; the appropriate choice depends on the clinical goal.

How long does an NAD+ IV infusion take?

Protocols commonly run several hours. The duration is deliberate — faster administration reliably produces chest tightness, cramping, and nausea, all of which are rate-dependent.

What does NAD+ do for aging?

NAD+ is required for sirtuin activity and mitochondrial energy production, both of which decline with age. Restoring NAD+ availability is a well-supported biochemical rationale. Demonstrating that it produces measurable clinical anti-aging outcomes in humans is a separate question that current trials have not settled.

Is NAD+ a peptide?

No. NAD+ is a dinucleotide coenzyme, not a peptide. It is often grouped with peptide therapies in clinical practice because it appears in similar longevity and performance protocols, but the biochemistry is unrelated.

Are there side effects to NAD+ injections?

The most common effects are infusion-rate dependent: chest pressure, abdominal cramping, nausea, flushing, and headache during IV administration. Subcutaneous administration more commonly produces injection-site discomfort. Both should be given under provider direction.

Positioning NAD+ in a Longevity Program

NAD+ has an unusually solid biochemical rationale and an unusually noisy commercial environment around it. The cellular biology is not in dispute: NAD+ declines with age, sirtuins depend on it, and precursor supplementation raises it. What remains open is whether — and in whom — that increase produces outcomes patients can feel or measure. Presenting it on those terms, and choosing the route that matches the actual clinical objective, is the difference between a considered protocol and an expensive infusion.